ReviewPediatric cardiology2026
The Use of Pulmonary Vasodilators in Pediatric Patients with Single-Ventricle Palliation: A Ten-Year Experience in a Tertiary Care Center.
Review in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In single-ventricle circulation, pulmonary vascular resistances (PVR) play a crucial role at various stages of surgical palliation. Increased PVR detected at cardiac catheterization represents a contraindication to Fontan completion and may lead to an early circuit failure in the postoperative period. Pulmonary vasodilator therapy (PVT) may lower PVR and enhance pre- and post-surgical outcomes in Fontan patients. This study reports the experience with the use of PVT in a tertiary center, focusing on its role in lowering PVR before Fontan procedure and assessing its impact on postoperative outcomes. We analyzed 151 pediatric patients with single-ventricle heart diseases in pre-Fontan stage at our institution from January 2014 to December 2023, collecting demographics, anatomical diagnoses, clinical history, administration of PVT, surgical complications, pre-Fontan hemodynamic parameters, duration of intubation, chest tube retention, oxygen therapy needs, and total hospitalization time. In 17 out of 18 patients (94.4%) who were previously considered unsuitable for Fontan completion, a significant decrease in PVR (p = 0.006) was observed after starting PVT, enabling surgery to be performed. Among 113 patients (74.8%) undergoing Fontan, no differences in postoperative outcomes were observed between those who received PVT in the pre-Fontan stage and those who did not. PVT was started in 50 out of 113 patients (44.2%) after surgery, primarily due to elevated pulmonary pressures on invasive monitoring; among them, 24 patients (48%) had already been on therapy prior to the operation. PVT in the postoperative period was associated with worse outcomes compared to patients not receiving therapy, likely due to the more severe conditions of treated patients. The use of PVT during the pre-Fontan stage increases the number of individuals eligible for surgical palliation, with minimal impact on postoperative outcomes.
Indexed as
Identifiers
40347271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.